BRIEF-Myriad Genetics, Beigene sign agreement – Reuters

April 6 Myriad Genetics Inc:

* Myriad Genetics and Beigene sign agreement to develop companion diagnostics for use with Beigene's novel parp inhibitor, BGB-290

* Myriad Genetics Inc - specific terms of deal were not disclosed.

* Myriad Genetics-under deal Beigene to use co's mychoice HRD, bracanalysis CDX companion diagnostic tests to support clinical development of BGB-290 Source text for Eikon: Further company coverage:

* Says it buys 50 percent stake in Barrick Gold's Veladero gold mine in Argentina for $960 million

* Cardiome's partner steadymed announces successful completion of trevyent clinical validation study

* Ant Financial Services Group says issued letter to Moneygram Community as it relates to Ant Financial's agreement to merge with Moneygram

Go here to see the original:
BRIEF-Myriad Genetics, Beigene sign agreement - Reuters

Related Posts